ERBB2 and non-small cell lung carcinoma: Recently, the FDA granted accelerated approval for fam-trastuzumab deruxtecan-nxki (T-DXd) as a second or further line of therapy for patients with HER2-mutant NSCLC, based on DESTINY-Lung01 and DESTINY-Lung02 trials.